Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19

NCT04327388 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04327388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04327388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
March 28, 2020
Completion date
September 2, 2020
Enrollment
420 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection